# GLP-1 Drugs for Weight Loss: Benefits, Risks, and Future Research **By Village Green Nutrition Team** · 2026-03-04 **By Kelly Dorfman, MS, LND ** _At Village Green, staying current with emerging research isn't just a priority, it's part of how we serve you. GLP-1 medications are one of the most talked-about developments in metabolic health and weight loss right now, and the science is still evolving. What we do know is that most people taking these medications receive little guidance beyond the prescription itself. Emerging research is revealing significant concerns around nutrient deficiencies, muscle loss, and side effects, areas where nutritional expertise is essential, yet often absent from the conversation._ _What makes the difference is personalized support. No two people respond to these medications the same way — your nutrient needs, side effects, and health goals are unique to you. Whether you're considering GLP-1s, currently on them, looking to wean off, or curious about natural alternatives, our team can provide individualized guidance to help you feel your best, tolerate the medication well, and achieve lasting results._ _We're proud to share this guest perspective from Kelly Dorfman, MS, LND, who brings both clinical insight and a whole-person approach to this conversation. This is part of our ongoing coverage of GLP-1 medications, because we believe you deserve practical, expert-backed information to ensure you're making the smartest decisions for your health. As the science evolves, we'll keep bringing you the latest perspectives and guidance._ ![](https://cdn.shopify.com/s/files/1/0319/0960/9603/files/GLP-1_Drugs_for_Weight_Loss_Benefits_Risks_and_Future_Research.png?v=1772703901)“I lost five pounds but put it back on again,” sighed Latissa\*. This was a typical update on the 56-year-old’s decades-long struggle with her weight. The only thing she seemed to have permanently lost was her self-esteem. “In more bad news,” she continued, “my blood pressure is up.” Given her high-pressure job, frequent cross-country travel, prediabetes markers, and forty-five extra pounds, the news was not surprising. Her doctor recommended a GLP-1 medication, but she declined. “I can do this without medication,” she said firmly. “This time I will stick with the plan.” We had this conversation many times before. Latissa knew what to do. The challenge was maintaining a strict low-carbohydrate diet for months at a time. She had successfully lost weight many times, only to regain it when work travel or family demands interrupted her routine. I gently suggested another perspective. “You can lose weight without medication, but for some very real biological reasons your progress has been limited. It may be time to consider how GLP-1 drugs could change the conversation about weight loss.” Latissa hesitated. She had heard about side effects and worried about becoming dependent on medication. Her hesitation is understandable. GLP-1 medications have moved quickly from specialized diabetes treatments to a highly visible and often controversial topic in the public health conversation. Before forming strong opinions, it helps to understand what GLP-1 is and why these medications are reshaping how we think about appetite, metabolism, and obesity treatment. ## Understanding GLP-1: The Hormone Changing Weight Loss Treatment GLP-1 stands for glucagon-like peptide-1, a hormone produced in the gut and brain that helps regulate blood sugar and appetite. This hormone increases insulin sensitivity and signals fullness after eating. Because natural hormones cannot be patented, pharmaceutical companies created medications that mimic GLP-1. These medications are significantly stronger and remain active in the body for about a week instead of minutes. GLP-1 research originally began with studies in lizards, but early medications introduced in 2005 were relatively weak and did not lead to meaningful weight loss. The breakthrough came in 2017 when semaglutide was approved for type 2 diabetes treatment. Patients soon noticed a powerful side effect: significant weight loss. ## How GLP-1 Medications Work ### Semaglutide: Ozempic and Wegovy Semaglutide, sold under the brand names Ozempic and Wegovy, slows digestion and reduces the amount of glucose released after eating. It also targets appetite centers in the brainstem that regulate hunger and fullness signals. By acting on these pathways, the medication significantly reduces appetite. However, these same mechanisms can cause gastrointestinal symptoms such as nausea and vomiting. Approximately one-third of patients stop semaglutide because of side effects. ### Tirzepatide: Mounjaro and Zepbound Tirzepatide, marketed as Mounjaro and Zepbound, represents the next generation of GLP-1 medications. Tirzepatide combines GLP-1 with another hormone called gastric inhibitory polypeptide, or GIP. This combination may reduce nausea and produce slightly greater weight loss compared with earlier GLP-1 drugs. ## The Growing Popularity of GLP-1 Drugs GLP-1 medications have rapidly become one of the most widely discussed developments in obesity treatment. Millions of Americans have tried them, and many more are considering them. However, the popularity of these drugs raises questions about accessibility and cost. Monthly treatment can exceed one thousand dollars without insurance coverage. While compounding pharmacies have created lower-cost alternatives, regulatory scrutiny continues to evolve. Oral versions of GLP-1 medications are also entering the market. Early studies suggest these forms may produce slightly less weight loss than injectable medications, but they may offer more flexible dosing and improved access for some patients. ## Scientific Revelations About GLP-1 and Metabolic Health One of the most surprising findings from recent research is that GLP-1 medications appear to protect cardiovascular health even before substantial weight loss occurs. A major study following more than 17,000 individuals over four years found no correlation between the amount of weight lost and the reduction in stroke, heart attack, and cardiovascular disease risk. This suggests that metabolic inflammation from overeating may be a major driver of disease risk independent of body weight itself. Another important insight involves the concept of food noise. Many individuals experience persistent mental signals about food that drive cravings and overeating. GLP-1 medications appear to quiet these signals in many patients. This discovery challenges long-held assumptions that weight struggles are simply a matter of discipline or willpower. Biological differences in appetite signaling may play a much larger role than previously understood. ### The Good: Potential Health Benefits of GLP-1 Drugs - Research evaluating thousands of clinical outcomes across multiple studies has reported improvements in metabolic, cardiovascular, endocrine, respiratory, and cognitive health markers. Some studies suggest reduced overall mortality in certain populations. - Additional research involving more than two million diabetic veterans found improvements in behavioral health outcomes, including reductions in suicidal ideation, bulimia, and severe psychiatric disorders. - Professional support can help manage potential nutritional challenges. Because calorie intake often decreases significantly, maintaining adequate intake of protein, fiber, vitamins, and minerals becomes more difficult. Nutritional guidance and strength training can help protect muscle mass and minimize side effects. - For many patients, the most profound benefit is the disappearance of constant food cravings. Many describe a sense of relief when the persistent mental focus on food finally subsides. - Working with prescribers to use the lowest effective dose, rather than pushing to maximum dosage and rapid weight loss, may lead to slower weight loss but fewer side effects for some patients. - Weight-bearing exercise can help reduce the risk of muscle loss and can be done inexpensively. ### The Bad: Risks and Limitations - Long-term effects remain uncertain. Studies have identified potential increases in diabetic retinopathy, gastrointestinal complications, and metabolic disturbances in some patients. - Reported side effects include nausea, vomiting, constipation, diarrhea, pancreatitis, gastroparesis, thyroid nodules, kidney problems, hair loss, and muscle loss. - Weight often returns to previous levels after discontinuing treatment, and health improvements may diminish as well. - Access disparities exist. Communities with higher obesity rates may face greater barriers to obtaining GLP-1 medications due to healthcare access and insurance coverage. - Cost remains a major limitation. Even with recent price reductions, these medications remain expensive for many individuals. - Some people do not lose weight on these medications, and some report appetite suppression that feels excessive. ### The Promising Future of GLP-1 Therapies - Pharmaceutical research continues to explore new medications that build upon the GLP-1 mechanism. Retatrutide, a triple receptor agonist, has produced weight loss approaching thirty percent in clinical trials. - Researchers are investigating whether low-dose GLP-1 therapies could help treat autoimmune disease. - Because these medications influence reward pathways in the brain, they may affect behaviors related to alcohol, gambling, shopping, and other compulsive behaviors. Studies are underway. - Oral versions currently in development may provide patients with more flexibility and individualized dosing options. - Among people with existing substance use disorders, the medications were associated with fewer drug related emergency department visits, hospital admissions, and deaths. This translated into roughly 12 fewer serious events per 1000 users over three years, including two fewer deaths. Crucially, we also saw clear reductions in drug overdoses and suicide attempts, suggesting these drugs may reduce some of the most lethal consequences of addiction. ## Why Support and Nutrition Guidance Matter Latissa eventually agreed to try tirzepatide under careful supervision. Her prescriber started with the lowest possible dose, and we adjusted her nutrition and supplement program to help minimize side effects and support metabolic health. A month later, she reported feeling emotionally lighter as well as physically healthier. The constant stress surrounding food had finally quieted. Her experience highlights an important reality. GLP-1 medications can be powerful tools, but they work best when combined with professional support, personalized nutrition strategies, and lifestyle changes that protect long-term metabolic health. At the same time, individual reports of unexpected side effects, such as reduced interest in previously enjoyable activities, suggest these medications may influence motivation and reward in complex ways. As use expands beyond weight loss and diabetes into additional applications, we may learn more about benefits as well as trade-offs. * * * ## About Our Guest Contributor _Kelly Dorfman, MS, LND is a licensed clinical nutritionist that specializes in targeted nutrition therapy to address complex medical problems.  Cure Your Child with Food, her awarding winning book about the surprising ways nutrition impacts common childhood ailments is published in 8 languages. An updated version was released in early 2021._  _Kelly lectures internationally and has been featured on numerous television programs and in periodical including CNN’s American Morning, the Wall Street Journal, the Washington Post, Oprah magazine and WebMD.  She was an adjunct professor at John Hopkins University for two years and is on the advisory board of the Gateway School of Mumbai._  _![](https://cdn.shopify.com/s/files/1/0319/0960/9603/files/Untitled_design_cb0b6a5e-0a37-4fb4-8838-15208d102665.png?v=1772705328)_ [**_Kelly Dorfman's website_**](https://kellydorfman.com/) * * * ## Frequently Asked Questions About GLP-1 Drugs ### What are GLP-1 drugs and how do they work? GLP-1 drugs are medications that mimic the glucagon-like peptide-1 hormone, which helps regulate blood sugar, slow digestion, and increase feelings of fullness. These effects can reduce appetite and support weight loss. ### Which GLP-1 medications are used for weight loss? Common GLP-1 medications used for weight loss include semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). These medications support appetite regulation and metabolic health. ### What are the most common side effects of GLP-1 drugs? Common side effects include nausea, vomiting, constipation, diarrhea, and reduced appetite. Some individuals also experience gastrointestinal discomfort or fatigue. ### Do people regain weight after stopping GLP-1 medications? Many people regain weight after stopping GLP-1 medications because the appetite-regulating effects of the drug stop. Long-term lifestyle strategies can help support maintenance. ### Can lifestyle and nutrition improve results with GLP-1 drugs? Yes. Adequate protein intake, fiber consumption, strength training, and personalized nutrition guidance can help improve outcomes and reduce side effects while using GLP-1 medications. _\* Not her real name._ ## References - Brookshire B. The next wave of GLP-1 drugs is coming and they are stronger than Wegovy and Zepbound. Scientific American. Feb 6, 2026. - Kong F et al. Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple disease. Nature Communications. 2026; 17:972. - Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023; 389:221-2232. - Moiz A et al. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. eClinicalMedicine. 2025; 86:103363. - Rodriguez LA et al. Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Lancet. 2024; 34:100759. - West S et al. Weight regain after cessation of medication for weight management: Systematic review and meta-analysis. BMJ. 2026; 392:e085304. - Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature Medicine. 2025. - Yeo YH et al. Shifting trends in the indication of glucagon-like peptide-1 receptor agonist prescriptions: A nationwide analysis. Annals of Internal Medicine. 2024; 177(9). - Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study _BM_J 2026; 392 doi: https://doi.org/10.1136/bmj-2025-086886 (Published 04 March 2026)Cite this as: BMJ 2026;392:e086886 **Tags:** appetite control, blood sugar balance, Category_GLP-1 Support, food noise, functional medicine nutrition, GLP-1 drugs, insulin resistance, metabolic health, Mounjaro, obesity treatment, Ozempic, semaglutide, tirzepatide, Wegovy, weight loss medications, weight management support --- > Source: [Village Green Apothecary](https://myvillagegreen.com/blogs/post/glp-1-drugs-for-weight-loss-benefits-risks-and-future-research)